{"id":64003,"date":"2026-04-27T13:38:25","date_gmt":"2026-04-27T05:38:25","guid":{"rendered":"https:\/\/flcube.com\/?p=64003"},"modified":"2026-04-27T13:38:26","modified_gmt":"2026-04-27T05:38:26","slug":"astrazeneca-secures-dual-nmpa-approvals-for-imfinzi-based-regimens-in-advanced-hepatocellular-carcinoma-and-nsclc","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=64003","title":{"rendered":"AstraZeneca Secures Dual NMPA Approvals for Imfinzi-Based Regimens in Advanced Hepatocellular Carcinoma and NSCLC"},"content":{"rendered":"\n<p><strong>AstraZeneca plc<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/AZN:NYSE\">NYSE: AZN<\/a>) announced that China\u2019s <strong>National Medical Products Administration (NMPA)<\/strong> has granted approvals for two <strong>first-line immuno-oncology regimens<\/strong> in hard-to-treat cancers:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Imfinzi (durvalumab) + Imjudo (tremelimumab)<\/strong> for <strong>advanced or unresectable hepatocellular carcinoma (HCC)<\/strong><\/li>\n\n\n\n<li><strong>Durvalumab monotherapy<\/strong> for the same HCC indication<\/li>\n<\/ul>\n\n\n\n<p>This follows an early-April NMPA approval of the <strong>STRIDE regimen<\/strong> (single tremelimumab priming dose + durvalumab) combined with platinum-based chemotherapy for <strong>first-line metastatic non-small cell lung cancer (NSCLC)<\/strong> in patients with <strong>EGFR\/ALK-negative status<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Full marketing authorization<\/td><\/tr><tr><td><strong>Products<\/strong><\/td><td>Imfinzi (durvalumab) \u00b1 Imjudo (tremelimumab)<\/td><\/tr><tr><td><strong>Indications<\/strong><\/td><td>1. Advanced\/unresectable HCC (combo &amp; mono)<br>2. Metastatic NSCLC (combo + chemo)<\/td><\/tr><tr><td><strong>Basis<\/strong><\/td><td>Global Phase III <strong>HIMALAYA trial<\/strong> + China cohort<\/td><\/tr><tr><td><strong>Commercial Launch<\/strong><\/td><td>Immediate availability through hospital channels<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-evidence-himalaya-trial-highlights\">Clinical Evidence \u2013 HIMALAYA Trial Highlights<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-global-cohort-all-patients\">Global Cohort (All Patients)<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>STRIDE vs. Sorafenib<\/strong>: <strong>22% reduction in death risk<\/strong> (HR 0.78; p=0.0035)<\/li>\n\n\n\n<li><strong>Median OS<\/strong>: <strong>16.4 months<\/strong> (STRIDE) vs. 13.8 months (sorafenib)<\/li>\n\n\n\n<li><strong>Durvalumab mono<\/strong>: Non-inferior to sorafenib (HR 0.86; median OS 16.6 months)<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-china-cohort-key-differentiator\">China Cohort (Key Differentiator)<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>STRIDE vs. Sorafenib<\/strong>: <strong>40% reduction in death risk<\/strong> (HR 0.60; 95% CI: 0.42\u20130.84)<\/li>\n\n\n\n<li><strong>Median OS<\/strong>: <strong>25.3 months<\/strong> vs. 14.1 months (<strong>+11.2 months<\/strong>)<\/li>\n\n\n\n<li><strong>3-Year OS Rate<\/strong>: <strong>40.6%<\/strong> (STRIDE) vs. ~20% (sorafenib)<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-safety-profile-favorable-tolerability\">Safety Profile \u2013 Favorable Tolerability<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Arm<\/th><th>Grade \u22653 TRAEs<\/th><\/tr><\/thead><tbody><tr><td><strong>STRIDE<\/strong><\/td><td>24.1%<\/td><\/tr><tr><td><strong>Durvalumab mono<\/strong><\/td><td>12.4%<\/td><\/tr><tr><td><strong>Sorafenib<\/strong><\/td><td>40.2%<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>Both regimens demonstrated significantly lower high-grade toxicity than the tyrosine kinase inhibitor standard.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-strategic-implications\">Market Impact &amp; Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>HCC Landscape<\/strong>: China accounts for >50% of global HCC cases; first-line immuno-oncology options remain limited despite high unmet need.<\/li>\n\n\n\n<li><strong>Pricing &amp; Access<\/strong>: AstraZeneca expects inclusion in <strong>2026 National Reimbursement Drug List (NRDL)<\/strong> negotiations, critical for volume uptake.<\/li>\n\n\n\n<li><strong>Competitive Positioning<\/strong>: STRIDE\u2019s dual checkpoint inhibition (PD-L1 + CTLA-4) offers a differentiated mechanism versus single-agent PD-1 inhibitors dominating China\u2019s market.<\/li>\n\n\n\n<li><strong>Revenue Catalyst<\/strong>: Analysts project peak annual sales of <strong>$300\u2013500 million<\/strong> in China across HCC and NSCLC indications by 2028.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding commercial performance, regulatory pathways, and clinical adoption. Actual outcomes may vary due to reimbursement dynamics, competitive pressures, and real-world evidence generation.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>AstraZeneca plc (NYSE: AZN) announced that China\u2019s National Medical Products Administration (NMPA) has granted approvals&#8230;<\/p>\n","protected":false},"author":1,"featured_media":64006,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[130,16,29,4621,15],"class_list":["post-64003","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-astrazeneca","tag-cancer","tag-combination-therapy","tag-nyse-azn","tag-product-approvals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>AstraZeneca Secures Dual NMPA Approvals for Imfinzi-Based Regimens in Advanced Hepatocellular Carcinoma and NSCLC - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"AstraZeneca plc (NYSE: AZN) announced that China\u2019s National Medical Products Administration (NMPA) has granted approvals for two first-line immuno-oncology regimens in hard-to-treat cancers:Imfinzi (durvalumab) + Imjudo (tremelimumab) for advanced or unresectable hepatocellular carcinoma (HCC)Durvalumab monotherapy for the same HCC indication\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=64003\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AstraZeneca Secures Dual NMPA Approvals for Imfinzi-Based Regimens in Advanced Hepatocellular Carcinoma and NSCLC\" \/>\n<meta property=\"og:description\" content=\"AstraZeneca plc (NYSE: AZN) announced that China\u2019s National Medical Products Administration (NMPA) has granted approvals for two first-line immuno-oncology regimens in hard-to-treat cancers:Imfinzi (durvalumab) + Imjudo (tremelimumab) for advanced or unresectable hepatocellular carcinoma (HCC)Durvalumab monotherapy for the same HCC indication\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=64003\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-27T05:38:25+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-27T05:38:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2701.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64003#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64003\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"AstraZeneca Secures Dual NMPA Approvals for Imfinzi-Based Regimens in Advanced Hepatocellular Carcinoma and NSCLC\",\"datePublished\":\"2026-04-27T05:38:25+00:00\",\"dateModified\":\"2026-04-27T05:38:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64003\"},\"wordCount\":327,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64003#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/2701.webp\",\"keywords\":[\"AstraZeneca\",\"Cancer\",\"Combination therapy\",\"NYSE:\u202fAZN\",\"Product approvals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=64003#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64003\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=64003\",\"name\":\"AstraZeneca Secures Dual NMPA Approvals for Imfinzi-Based Regimens in Advanced Hepatocellular Carcinoma and NSCLC - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64003#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64003#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/2701.webp\",\"datePublished\":\"2026-04-27T05:38:25+00:00\",\"dateModified\":\"2026-04-27T05:38:26+00:00\",\"description\":\"AstraZeneca plc (NYSE: AZN) announced that China\u2019s National Medical Products Administration (NMPA) has granted approvals for two first-line immuno-oncology regimens in hard-to-treat cancers:Imfinzi (durvalumab) + Imjudo (tremelimumab) for advanced or unresectable hepatocellular carcinoma (HCC)Durvalumab monotherapy for the same HCC indication\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64003#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=64003\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64003#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/2701.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/2701.webp\",\"width\":1080,\"height\":608,\"caption\":\"AstraZeneca Secures Dual NMPA Approvals for Imfinzi-Based Regimens in Advanced Hepatocellular Carcinoma and NSCLC\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64003#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AstraZeneca Secures Dual NMPA Approvals for Imfinzi-Based Regimens in Advanced Hepatocellular Carcinoma and NSCLC\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"AstraZeneca Secures Dual NMPA Approvals for Imfinzi-Based Regimens in Advanced Hepatocellular Carcinoma and NSCLC - Insight, China&#039;s Pharmaceutical Industry","description":"AstraZeneca plc (NYSE: AZN) announced that China\u2019s National Medical Products Administration (NMPA) has granted approvals for two first-line immuno-oncology regimens in hard-to-treat cancers:Imfinzi (durvalumab) + Imjudo (tremelimumab) for advanced or unresectable hepatocellular carcinoma (HCC)Durvalumab monotherapy for the same HCC indication","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=64003","og_locale":"en_US","og_type":"article","og_title":"AstraZeneca Secures Dual NMPA Approvals for Imfinzi-Based Regimens in Advanced Hepatocellular Carcinoma and NSCLC","og_description":"AstraZeneca plc (NYSE: AZN) announced that China\u2019s National Medical Products Administration (NMPA) has granted approvals for two first-line immuno-oncology regimens in hard-to-treat cancers:Imfinzi (durvalumab) + Imjudo (tremelimumab) for advanced or unresectable hepatocellular carcinoma (HCC)Durvalumab monotherapy for the same HCC indication","og_url":"https:\/\/flcube.com\/?p=64003","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-27T05:38:25+00:00","article_modified_time":"2026-04-27T05:38:26+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2701.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=64003#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=64003"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"AstraZeneca Secures Dual NMPA Approvals for Imfinzi-Based Regimens in Advanced Hepatocellular Carcinoma and NSCLC","datePublished":"2026-04-27T05:38:25+00:00","dateModified":"2026-04-27T05:38:26+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=64003"},"wordCount":327,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=64003#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2701.webp","keywords":["AstraZeneca","Cancer","Combination therapy","NYSE:\u202fAZN","Product approvals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=64003#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=64003","url":"https:\/\/flcube.com\/?p=64003","name":"AstraZeneca Secures Dual NMPA Approvals for Imfinzi-Based Regimens in Advanced Hepatocellular Carcinoma and NSCLC - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=64003#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=64003#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2701.webp","datePublished":"2026-04-27T05:38:25+00:00","dateModified":"2026-04-27T05:38:26+00:00","description":"AstraZeneca plc (NYSE: AZN) announced that China\u2019s National Medical Products Administration (NMPA) has granted approvals for two first-line immuno-oncology regimens in hard-to-treat cancers:Imfinzi (durvalumab) + Imjudo (tremelimumab) for advanced or unresectable hepatocellular carcinoma (HCC)Durvalumab monotherapy for the same HCC indication","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=64003#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=64003"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=64003#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2701.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2701.webp","width":1080,"height":608,"caption":"AstraZeneca Secures Dual NMPA Approvals for Imfinzi-Based Regimens in Advanced Hepatocellular Carcinoma and NSCLC"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=64003#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"AstraZeneca Secures Dual NMPA Approvals for Imfinzi-Based Regimens in Advanced Hepatocellular Carcinoma and NSCLC"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2701.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64003","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=64003"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64003\/revisions"}],"predecessor-version":[{"id":64007,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64003\/revisions\/64007"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/64006"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=64003"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=64003"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=64003"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}